Michael Diamond

Michael Diamond is a Clinical Care Coordinator at Columbia University and a Senior Professor, serving as Associate Director of the Center for Human Immunology and Immunotherapy Programs at Washington University. He earned his BA from Columbia College (1985), followed by an MD from Harvard Medical School and a PhD from Harvard University (1994). His research focuses on viral immunology, specifically SARS-CoV-2 variant neutralization, alphavirus receptor biology, and arenavirus host factors. Notable publications include work on LDLRAD3 as a receptor for Venezuelan equine encephalitis virus (Nature, 2021) and SARS-CoV-2 antibody resistance (Nature Medicine, 2021). His recent studies address pan-encephalitic alphavirus receptor decoys and Fc-engineered antibodies against lung infection. He received the Korsmeyer Award (2019), Chancellor’s Award for Innovation and Entrepreneurship (2023), and was elected to the National Academy of Sciences (2024).